Table 2. Immunohistochemistry results in high-grade serous ovarian carcinoma.
p53 | MDR1 | EGFR | HER2 | ER | PR | |
---|---|---|---|---|---|---|
Examined | 119 (98.3%) |
112 (92.6%) |
111 (91.7%) |
120 (99.2%) |
113 (93.4%) |
112 (92.6%) |
Positivity | 85 (71.4%) |
16 (14.3%) |
63 (52.1%) |
82 (68.3%) |
98 (86.7%) |
10 (8.9%) |
Staining intensity | ||||||
0 | 34 (28.6%) |
96 (85.7%) |
48 (43.2%) |
38 (31.7%) |
15 (13.3%) |
101 (90.2%) |
1+ | 1 (0.8%) |
11 (9.8%) |
15 (13.5%) |
50 41.7%) |
23 (20.4%) |
1 (0.9%) |
2+ | 7 (5.9%) |
2 (1.8%) |
33 (29.7%) |
26 (21.7%) |
51 (45.1%) |
4 (3.6%) |
3+ | 77 (64.7%) |
3 (2.7%) |
15 (13.5%) |
6 (5.0%) |
24 (21.2%) |
6 (5.4%) |
Percent expression | ||||||
0% | 34 (28.6%) |
96 (85.7%) |
48 (43.2%) |
38 (31.7%) |
15 (13.3%) |
101 (90.2%) |
1-25% | 10 (8.4%) |
10 (8.9%) |
37 (33.3%) |
37 (30.8%) |
29 (25.7%) |
9 (8.0%) |
26-50% | 4 (3.4%) |
4 (3.6%) |
16 (14.4%) |
20 (16.7%) |
27 (23.9%) |
0 (0%) |
51-75% | 5 (4.2%) |
1 (0.9%) |
3 (2.7%) |
13 (10.8%) |
22 (19.5%) |
2 (1.7%) |
76-100% | 66 (55.5%) |
1 (0.9%) |
7 (6.3%) |
12 (10.0%) |
20 (17.7%) |
0 (0%) |
Positivity of immunohistochemistry results was defined as proportional expression of ≥5% and staining intensity of ≥1+. Abbreviations: MDR1, multi-drug resistance 1; EGFR, epidermal growth factor receptor, HER2, human epidermal growth factor receptor 2; ER, estrogen receptor alpha; and PR, progesterone receptor.